{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31267009", "DateCompleted": {"Year": "2020", "Month": "10", "Day": "16"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "07", "Day": "02"}], "Language": ["eng"], "ELocationID": ["9527", "10.1038/s41598-019-45974-7"], "Journal": {"ISSN": "2045-2322", "JournalIssue": {"Volume": "9", "Issue": "1", "PubDate": {"Year": "2019", "Month": "Jul", "Day": "02"}}, "Title": "Scientific reports", "ISOAbbreviation": "Sci Rep"}, "ArticleTitle": "Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.", "Pagination": {"StartPage": "9527", "MedlinePgn": "9527"}, "Abstract": {"AbstractText": ["Galbanic acid (Gba), a sesquiterpene coumarin, with strong antiangiogenic activity could serve as an excellent anti-cancer agent. However, Gba is a poor water-solube which hampered its clinical application. In this study, a pegylated liposomal Gba (PLGba) with HSPC/Cholesterol/mPEG<sub>2000</sub>-DSPE (56.2, 38.3, 5.3% molar ratio) was developed by the thin film hydration plus extrusion and calcium acetate gradient remote loading method, to address the issue of poor Gba solubility. Moreover, an integrin-targeting ligand (RGD peptide, cyclo[Arg-Gly-Asp-D-Tyr-Cys]) was post-inserted into liposomes in order to increase Gba cell delivery. Using fluorescently-labeled model liposomes, it was found that the targeting could improve the integrin-mediated cellular uptake of the liposomes in vitro in human umbilical vein endothelial cells (HUVECs), and in vivo as evidenced by chicken chorioallantoic membrane angiogenesis (CAM) model. It also could enrich the liposome accumulation in C26 tumor. Interestingly, co-treatment with PLGba and pegylated liposomal doxorubicin (PLD, also known as Doxil<sup>\u00ae</sup>) had a synergistic and antagonistic antiproliferative effect on the C26 tumor cell line and the normal HUVEC, respectively. In C26 tumor bearing BALB/c mice, the PLGba and PLD combinatorial therapy improved the antitumor efficacy of the treatment as compared to those of single agents. This results have clear implications for cancer therapy."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Nik", "ForeName": "Maryam Ebrahimi", "Initials": "ME"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Malaekeh-Nikouei", "ForeName": "Bizhan", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands."}], "LastName": "Amin", "ForeName": "Mohamadreza", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Hatamipour", "ForeName": "Mahdi", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran."}], "LastName": "Teymouri", "ForeName": "Manouchehr", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Sadeghnia", "ForeName": "Hamid Reza", "Initials": "HR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Iranshahi", "ForeName": "Mehrdad", "Initials": "M"}, {"Identifier": ["0000-0003-3908-6828"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Jafarimr@mums.ac.ir."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Jafarimr@mums.ac.ir."}], "LastName": "Jaafari", "ForeName": "Mahmoud Reza", "Initials": "MR"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Sci Rep", "NlmUniqueID": "101563288", "ISSNLinking": "2045-2322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Coumarins"}, {"RegistryNumber": "0", "NameOfSubstance": "Liposomes"}, {"RegistryNumber": "0", "NameOfSubstance": "Oligopeptides"}, {"RegistryNumber": "0", "NameOfSubstance": "liposomal doxorubicin"}, {"RegistryNumber": "3WJQ0SDW1A", "NameOfSubstance": "Polyethylene Glycols"}, {"RegistryNumber": "78VO7F77PN", "NameOfSubstance": "arginyl-glycyl-aspartic acid"}, {"RegistryNumber": "80168379AG", "NameOfSubstance": "Doxorubicin"}, {"RegistryNumber": "9OFS0HWC92", "NameOfSubstance": "galbanic acid"}], "CommentsCorrectionsList": [{"RefSource": "Sci Rep. 2020 Feb 27;10(1):3965. doi: 10.1038/s41598-020-60918-2", "PMID": "32103120"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemistry", "pharmacokinetics", "pharmacology", "therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["drug therapy", "mortality", "pathology"], "DescriptorName": "Colonic Neoplasms"}, {"QualifierName": ["chemistry", "pharmacokinetics", "pharmacology", "therapeutic use"], "DescriptorName": "Coumarins"}, {"QualifierName": ["analogs & derivatives", "chemistry", "pharmacokinetics", "pharmacology", "therapeutic use"], "DescriptorName": "Doxorubicin"}, {"QualifierName": [], "DescriptorName": "Drug Synergism"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Half-Life"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Liposomes"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": ["drug effects"], "DescriptorName": "Neovascularization, Physiologic"}, {"QualifierName": ["chemistry"], "DescriptorName": "Oligopeptides"}, {"QualifierName": ["chemistry", "pharmacokinetics", "pharmacology", "therapeutic use"], "DescriptorName": "Polyethylene Glycols"}, {"QualifierName": [], "DescriptorName": "Survival Rate"}, {"QualifierName": [], "DescriptorName": "Tissue Distribution"}, {"QualifierName": [], "DescriptorName": "Xenograft Model Antitumor Assays"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Zugazagoitia J, et al. Current challenges in cancer treatment. Clinical therapeutics. 2016;38:1551\u20131566. doi: 10.1016/j.clinthera.2016.03.026.", "ArticleIdList": ["10.1016/j.clinthera.2016.03.026", "27158009"]}, {"Citation": "Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal transduction and targeted therapy. 2018;3:7. doi: 10.1038/s41392-017-0004-3.", "ArticleIdList": ["10.1038/s41392-017-0004-3", "PMC5854578", "29560283"]}, {"Citation": "Liang, X.-J., Chen, C., Zhao, Y. & Wang, P. C. In Multi-Drug Resistance in Cancer 467\u2013488 (Springer, 2010)."}, {"Citation": "Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981\u20132002. Journal of natural products. 2003;66:1022\u20131037. doi: 10.1021/np030096l.", "ArticleIdList": ["10.1021/np030096l", "12880330"]}, {"Citation": "Grabley, S. & Thiericke, R. Drug discovery from nature. (Springer Science & Business Media, 1998)."}, {"Citation": "Kim K-H, et al. Galbanic acid isolated from Ferula assafoetida exerts in vivo anti-tumor activity in association with anti-angiogenesis and anti-proliferation. Pharmaceutical research. 2011;28:597\u2013609. doi: 10.1007/s11095-010-0311-7.", "ArticleIdList": ["10.1007/s11095-010-0311-7", "21063754"]}, {"Citation": "Kasaian J, Iranshahy M, Iranshahi M. Synthesis, biosynthesis and biological activities of galbanic acid\u2013A review. Pharmaceutical biology. 2014;52:524\u2013531. doi: 10.3109/13880209.2013.846916.", "ArticleIdList": ["10.3109/13880209.2013.846916", "24328450"]}, {"Citation": "Bedniak A. On the problem of the isolation of galbanic acid from Ferula gumosa Boiss. roots. Aptechnoe delo. 1962;12:28\u201334.", "ArticleIdList": ["13866469"]}, {"Citation": "Kiani A, et al. Combined spectroscopy and molecular modeling studies on the binding of galbanic acid and MMP9. International journal of biological macromolecules. 2015;81:308\u2013315. doi: 10.1016/j.ijbiomac.2015.08.005.", "ArticleIdList": ["10.1016/j.ijbiomac.2015.08.005", "26253511"]}, {"Citation": "Cha M-R, et al. Galbanic acid, a cytotoxic sesquiterpene from the gum resin of Ferula asafoetida, blocks protein farnesyltransferase. Planta medica. 2011;77:52\u201354. doi: 10.1055/s-0030-1250049.", "ArticleIdList": ["10.1055/s-0030-1250049", "20560115"]}, {"Citation": "Wang G, et al. Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert opinion on drug delivery. 2015;12:1475\u20131499. doi: 10.1517/17425247.2015.1021681.", "ArticleIdList": ["10.1517/17425247.2015.1021681", "25843160"]}, {"Citation": "Khadka P, et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian journal of pharmaceutical sciences. 2014;9:304\u2013316. doi: 10.1016/j.ajps.2014.05.005.", "ArticleIdList": ["10.1016/j.ajps.2014.05.005"]}, {"Citation": "Rajabi M, Mousa SA. Lipid nanoparticles and their application in nanomedicine. Current pharmaceutical biotechnology. 2016;17:662\u2013672. doi: 10.2174/1389201017666160415155457.", "ArticleIdList": ["10.2174/1389201017666160415155457", "27087491"]}, {"Citation": "Bozzuto G, Molinari A. Liposomes as nanomedical devices. International journal of nanomedicine. 2015;10:975. doi: 10.2147/IJN.S68861.", "ArticleIdList": ["10.2147/IJN.S68861", "PMC4324542", "25678787"]}, {"Citation": "Kumar M. Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharm. Sci. 2000;3:234\u2013258.", "ArticleIdList": ["10994037"]}, {"Citation": "Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced drug delivery reviews. 2013;65:71\u201379. doi: 10.1016/j.addr.2012.10.002.", "ArticleIdList": ["10.1016/j.addr.2012.10.002", "23088862"]}, {"Citation": "Ernsting MJ, Murakami M, Roy A, Li S-D. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. Journal of Controlled Release. 2013;172:782\u2013794. doi: 10.1016/j.jconrel.2013.09.013.", "ArticleIdList": ["10.1016/j.jconrel.2013.09.013", "PMC3891171", "24075927"]}, {"Citation": "Peer D, et al. Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology. 2007;2:751. doi: 10.1038/nnano.2007.387.", "ArticleIdList": ["10.1038/nnano.2007.387", "18654426"]}, {"Citation": "Hobbs SK, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proceedings of the National Academy of Sciences. 1998;95:4607\u20134612. doi: 10.1073/pnas.95.8.4607.", "ArticleIdList": ["10.1073/pnas.95.8.4607", "PMC22537", "9539785"]}, {"Citation": "Yuan F, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer research. 1995;55:3752\u20133756.", "ArticleIdList": ["7641188"]}, {"Citation": "Barenholz YC. Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned. Journal of controlled release. 2012;160:117\u2013134. doi: 10.1016/j.jconrel.2012.03.020.", "ArticleIdList": ["10.1016/j.jconrel.2012.03.020", "22484195"]}, {"Citation": "Barenholz, Y. Doxil-the first FDA-approved nano-drug: from an idea to a product. Handb. Harnessing Biomater. Nanomed, 335\u2013398 (2012)."}, {"Citation": "Heckmann D, et al. Probing integrin selectivity: rational design of highly active and selective ligands for the \u03b15\u03b21 and \u03b1v\u03b23 integrin receptor. Angewandte Chemie International Edition. 2007;46:3571\u20133574. doi: 10.1002/anie.200700008.", "ArticleIdList": ["10.1002/anie.200700008", "17394271"]}, {"Citation": "Heckmann D, Kessler H. Design and chemical synthesis of integrin ligands. Methods in enzymology. 2007;426:463\u2013503. doi: 10.1016/S0076-6879(07)26020-3.", "ArticleIdList": ["10.1016/S0076-6879(07)26020-3", "17697896"]}, {"Citation": "Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug resistance updates. 2005;8:381\u2013402. doi: 10.1016/j.drup.2005.10.002.", "ArticleIdList": ["10.1016/j.drup.2005.10.002", "16309948"]}, {"Citation": "Ragelle H, et al. Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosan\u2013poly (ethylene imine) hybrid nanoparticles: A mechanistic insight. Journal of Controlled Release. 2015;211:1\u20139. doi: 10.1016/j.jconrel.2015.05.274.", "ArticleIdList": ["10.1016/j.jconrel.2015.05.274", "25989603"]}, {"Citation": "Diou O, et al. RGD decoration of PEGylated polyester nanocapsules of perfluorooctyl bromide for tumor imaging: Influence of pre or post-functionalization on capsule morphology. European Journal of Pharmaceutics and Biopharmaceutics. 2014;87:170\u2013177. doi: 10.1016/j.ejpb.2013.12.003.", "ArticleIdList": ["10.1016/j.ejpb.2013.12.003", "24333400"]}, {"Citation": "Snipstad S, et al. Labeling nanoparticles: Dye leakage and altered cellular uptake. Cytometry Part A. 2017;91:760\u2013766. doi: 10.1002/cyto.a.22853.", "ArticleIdList": ["10.1002/cyto.a.22853", "27077940"]}, {"Citation": "Cressman S, et al. Binding and Uptake of RGD-Containing Ligands to Cellular \u03b1 v \u03b2 3 Integrins. International Journal of Peptide Research and Therapeutics. 2009;15:49\u201359. doi: 10.1007/s10989-008-9163-y.", "ArticleIdList": ["10.1007/s10989-008-9163-y"]}, {"Citation": "Amin M, Badiee A, Jaafari MR. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. International journal of pharmaceutics. 2013;458:324\u2013333. doi: 10.1016/j.ijpharm.2013.10.018.", "ArticleIdList": ["10.1016/j.ijpharm.2013.10.018", "24148663"]}, {"Citation": "Amin M, et al. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. Journal of Controlled Release. 2015;220:308\u2013315. doi: 10.1016/j.jconrel.2015.10.039.", "ArticleIdList": ["10.1016/j.jconrel.2015.10.039", "26526970"]}, {"Citation": "Wutzler P, Sauerbrei A, H\u00e4rtl A, Reimer K. Comparative testing of liposomal and aqueous formulations of povidone-iodine for their angioirritative potential at the chorioallantoic membrane of ex ovo cultivated chick embryos. Dermatology. 2003;207:43\u201347. doi: 10.1159/000070940.", "ArticleIdList": ["10.1159/000070940", "12835547"]}, {"Citation": "Ribatti D. Chick embryo chorioallantoic membrane as a useful tool to study angiogenesis. International review of cell and molecular biology. 2008;270:181\u2013224. doi: 10.1016/S1937-6448(08)01405-6.", "ArticleIdList": ["10.1016/S1937-6448(08)01405-6", "19081537"]}, {"Citation": "Ribatti, D. In Cardiovascular Development 47\u201357 (Springer, 2012)."}, {"Citation": "Lokman NA, Elder AS, Ricciardelli C, Oehler MK. Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. International journal of molecular sciences. 2012;13:9959\u20139970. doi: 10.3390/ijms13089959.", "ArticleIdList": ["10.3390/ijms13089959", "PMC3431839", "22949841"]}, {"Citation": "Yamasaki M, Muraki Y, Nishimoto Y, Murakawa Y, Matsuo T. Fluorescence-labeled liposome accumulation in injured colon of a mouse model of T-cell transfer-mediated inflammatory bowel disease. Biochemical and biophysical research communications. 2017;494:188\u2013193. doi: 10.1016/j.bbrc.2017.10.058.", "ArticleIdList": ["10.1016/j.bbrc.2017.10.058", "29037813"]}, {"Citation": "Ding J, Feng M, Wang F, Wang H, Guan W. Oncology reports. 2015. Targeting effect of PEGylated liposomes modified with the Arg-Gly-Asp sequence on gastric cancer; pp. 1825\u20131834.", "ArticleIdList": ["26238930"]}, {"Citation": "Knudsen KB, et al. Biodistribution of rhodamine B fluorescence-labeled cationic nanoparticles in rats. Journal of nanoparticle research. 2014;16:2221. doi: 10.1007/s11051-013-2221-1.", "ArticleIdList": ["10.1007/s11051-013-2221-1"]}, {"Citation": "Deissler V, et al. Fluorescent liposomes as contrast agents for in vivo optical imaging of edemas in mice. Small. 2008;4:1240\u20131246. doi: 10.1002/smll.200701069.", "ArticleIdList": ["10.1002/smll.200701069", "18666163"]}, {"Citation": "M\u00fcnter R, et al. Dissociation of fluorescently labeled lipids from liposomes in biological environments challenges the interpretation of uptake studies. Nanoscale. 2018;10:22720\u201322724. doi: 10.1039/C8NR07755J.", "ArticleIdList": ["10.1039/C8NR07755J", "30488936"]}, {"Citation": "Dijkgraaf I, et al. Synthesis and biological evaluation of potent \u03b1v\u03b23-integrin receptor antagonists. Nuclear medicine and biology. 2006;33:953\u2013961. doi: 10.1016/j.nucmedbio.2006.08.008.", "ArticleIdList": ["10.1016/j.nucmedbio.2006.08.008", "17127167"]}, {"Citation": "Chen X, Park R, Shahinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nuclear medicine and biology. 2004;31:11\u201319. doi: 10.1016/j.nucmedbio.2003.07.003.", "ArticleIdList": ["10.1016/j.nucmedbio.2003.07.003", "14741566"]}, {"Citation": "Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Molecular cancer therapeutics. 2008;7:3670\u20133684. doi: 10.1158/1535-7163.MCT-08-0715.", "ArticleIdList": ["10.1158/1535-7163.MCT-08-0715", "PMC2637411", "19074844"]}, {"Citation": "Iranshahi M, et al. Sesquiterpene coumarins from Ferula szowitsiana and in vitro antileishmanial activity of 7-prenyloxycoumarins against promastigotes. Phytochemistry. 2007;68:554\u2013561. doi: 10.1016/j.phytochem.2006.11.002.", "ArticleIdList": ["10.1016/j.phytochem.2006.11.002", "17196626"]}, {"Citation": "Moreira JN, Ishida T, Gaspar R, Allen TM. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharmaceutical research. 2002;19:265\u2013269. doi: 10.1023/A:1014434732752.", "ArticleIdList": ["10.1023/A:1014434732752", "11934232"]}, {"Citation": "Teymouri M, et al. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. International journal of pharmaceutics. 2016;511:236\u2013244. doi: 10.1016/j.ijpharm.2016.06.117.", "ArticleIdList": ["10.1016/j.ijpharm.2016.06.117", "27363937"]}, {"Citation": "Bartlett GR. Phosphorus assay in column chromatography. J Biol chem. 1959;234:466\u2013468.", "ArticleIdList": ["13641241"]}, {"Citation": "Strober, W. Trypan blue exclusion test of cell viability. Current protocols in immunology21, A. 3B. 1-A. 3B. 2 (1997).", "ArticleIdList": ["18432654"]}, {"Citation": "Jang C, Lee JH, Sahu A, Tae G. The synergistic effect of folate and RGD dual ligand of nanographene oxide on tumor targeting and photothermal therapy in vivo. Nanoscale. 2015;7:18584\u201318594. doi: 10.1039/C5NR05067G.", "ArticleIdList": ["10.1039/C5NR05067G", "26489965"]}, {"Citation": "Arabi L, Badiee A, Mosaffa F, Jaafari MR. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. Journal of controlled release. 2015;220:275\u2013286. doi: 10.1016/j.jconrel.2015.10.044.", "ArticleIdList": ["10.1016/j.jconrel.2015.10.044", "26518722"]}, {"Citation": "Li J, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC cancer. 2010;10:529. doi: 10.1186/1471-2407-10-529.", "ArticleIdList": ["10.1186/1471-2407-10-529", "PMC2984425", "20923544"]}]}], "History": [{"Year": "2019", "Month": "3", "Day": "12"}, {"Year": "2019", "Month": "6", "Day": "17"}, {"Year": "2019", "Month": "7", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "7", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "10", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "7", "Day": "2"}], "PublicationStatus": "epublish", "ArticleIdList": ["31267009", "PMC6606580", "10.1038/s41598-019-45974-7", "10.1038/s41598-019-45974-7"]}}]}